nach oben

Journal of Neurology

Erschienen in:

01.07.2015 | Original Communication

A longitudinal MRI study of cervical cord atrophy in multiple sclerosis

verfasst von: Paola Valsasina, Maria A. Rocca, Mark A. Horsfield, Massimiliano Copetti, Massimo Filippi

Erschienen in: Journal of Neurology | Ausgabe 7/2015

Einloggen, um Zugang zu erhalten

Abstract

There is an urgent need of fast and accurate methods for the longitudinal quantification of cervical cord atrophy in multiple sclerosis (MS). Aim of this study was to compare a new semi-automatic method [the active surface (AS) method] with an existing cord segmentation method (the Losseff method) to measure cervical cord atrophy progression in MS patients. Using the AS and Losseff methods, normalized cervical cord cross-sectional area (CSA) was compared between 35 MS patients and 9 healthy controls (HC) at baseline and after 2.3 years of follow-up. Correlations with clinical/conventional MRI variables and a power calculation study were also performed. At follow-up, the Losseff method detected a 1 % CSA increase in HC and a 3.5 % decrease in MS patients (p = 0.01), while the AS method detected a 0.1 % decrease in HC and 3 % decrease in MS patients (p = 0.02). The AS method was more sensitive to associations with disability/conventional MRI variables and also provided lower numbers of subjects per arm compared to the Losseff method in a putative clinical trial scenario. Cord AS CSA measurements were more sensitive to longitudinal changes in MS patients than Losseff measurements. Cord AS CSA might be a valuable surrogate outcome measure for monitoring neuroprotection in MS.

Nur mit Berechtigung zugänglich

Nijeholt GJ, van Walderveen MA, Castelijns JA et al (1998) Brain and spinal cord abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical subtypes and symptoms. Brain 121(Pt 4):687–697CrossRefPubMed

Evangelou N, DeLuca GC, Owens T, Esiri MM (2005) Pathological study of spinal cord atrophy in multiple sclerosis suggests limited role of local lesions. Brain 128(Pt 1):29–34PubMed

DeLuca GC, Ebers GC, Esiri MM (2004) Axonal loss in multiple sclerosis: a pathological survey of the corticospinal and sensory tracts. Brain 127(Pt 5):1009–1018CrossRefPubMed

Filippi M, Rocca MA (2013) Multiple sclerosis: Linking disability and spinal cord imaging outcomes in MS. Nat Rev Neurol 9(4):189–190CrossRefPubMed

Rashid W, Davies GR, Chard DT et al (2006) Increasing cord atrophy in early relapsing-remitting multiple sclerosis: a 3 year study. J Neurol Neurosurg Psychiatry 77(1):51–55PubMedCentralCrossRefPubMed

Losseff NA, Webb SL, O’Riordan JI et al (1996) Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 119(Pt 3):701–708CrossRefPubMed

Horsfield MA, Sala S, Neema M et al (2010) Rapid semi-automatic segmentation of the spinal cord from magnetic resonance images: application in multiple sclerosis. Neuroimage 50(2):446–455PubMedCentralCrossRefPubMed

Rocca MA, Horsfield MA, Sala S et al (2011) A multicenter assessment of cervical cord atrophy among MS clinical phenotypes. Neurology 76(24):2096–2102CrossRefPubMed

Lukas C, Sombekke MH, Bellenberg B et al (2013) Relevance of spinal cord abnormalities to clinical disability in multiple sclerosis: MR imaging findings in a large cohort of patients. Radiology 269(2):542–552CrossRefPubMed

10.

Kearney H, Rocca MA, Valsasina P et al (2014) Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease duration. Mult Scler 20(1):72–80PubMedCentralCrossRefPubMed

11.

Daams M, Weiler F, Steenwijk MD et al (2014) Mean upper cervical cord area (MUCCA) measurement in long-standing multiple sclerosis: Relation to brain findings and clinical disability. Mult Scler 20(14):1860–1865CrossRefPubMed

12.

Barkhof F, Calabresi PA, Miller DH, Reingold SC (2009) Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol 5(5):256–266CrossRefPubMed

13.

Zivadinov R, Reder AT, Filippi M et al (2008) Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology 71(2):136–144CrossRefPubMed

14.

Filippi M, Preziosa P, Rocca MA (2014) Magnetic resonance outcome measures in multiple sclerosis trials: time to rethink? Curr Opin Neurol 27(3):290–299CrossRefPubMed

15.

Vrenken H, Jenkinson M, Horsfield MA et al (2013) Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosis. J Neurol 260(10):2458–2471PubMedCentralCrossRefPubMed

16.

Ingle GT, Stevenson VL, Miller DH, Thompson AJ (2003) Primary progressive multiple sclerosis: a 5-year clinical and MR study. Brain 126(Pt 11):2528–2536CrossRefPubMed

17.

Lin X, Tench CR, Turner B, Blumhardt LD, Constantinescu CS (2003) Spinal cord atrophy and disability in multiple sclerosis over four years: application of a reproducible automated technique in monitoring disease progression in a cohort of the interferon beta-1a (Rebif) treatment trial. J Neurol Neurosurg Psychiatry 74(8):1090–1094PubMedCentralCrossRefPubMed

18.

Stevenson VL, Ingle GT, Miller DH, Thompson AJ (2004) Magnetic resonance imaging predictors of disability in primary progressive multiple sclerosis: a 5-year study. Mult Scler 10(4):398–401CrossRefPubMed

19.

Agosta F, Absinta M, Sormani MP et al (2007) In vivo assessment of cervical cord damage in MS patients: a longitudinal diffusion tensor MRI study. Brain 130(Pt 8):2211–2219CrossRefPubMed

20.

Furby J, Hayton T, Altmann D et al (2010) A longitudinal study of MRI-detected atrophy in secondary progressive multiple sclerosis. J Neurol 257(9):1508–1516CrossRefPubMed

21.

Lukas C, Knol DL, Sombekke MH et al (2015) Cervical spinal cord volume loss is related to clinical disability progression in multiple sclerosis. J Neurol Neurosurg Psychiatry 86(4):410–418CrossRefPubMed

22.

Stevenson VL, Leary SM, Losseff NA et al (1998) Spinal cord atrophy and disability in MS: a longitudinal study. Neurology. 51(1):234–238CrossRefPubMed

23.

Leary SM, Miller DH, Stevenson VL, Brex PA, Chard DT, Thompson AJ (2003) Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology 60(1):44–51CrossRefPubMed

24.

Montalban X, Sastre-Garriga J, Tintore M et al (2009) A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. Mult Scler 15(10):1195–1205CrossRefPubMed

25.

Klein JP, Arora A, Neema M et al (2011) A 3T MR imaging investigation of the topography of whole spinal cord atrophy in multiple sclerosis. AJNR Am J Neuroradiol 32(6):1138–1142PubMedCentralCrossRefPubMed

26.

Kearney H, Yiannakas MC, Abdel-Aziz K et al (2014) Improved MRI quantification of spinal cord atrophy in multiple sclerosis. J Magn Reson Imaging 39(3):617–623CrossRefPubMed

27.

Polman CH, Reingold SC, Banwell B et al (2010) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2):292–302CrossRef

28.

Lin X, Blumhardt LD, Constantinescu CS (2003) The relationship of brain and cervical cord volume to disability in clinical subtypes of multiple sclerosis: a three-dimensional MRI study. Acta Neurol Scand 108(6):401–406CrossRefPubMed

29.

Tench CR, Morgan PS, Constantinescu CS (2005) Measurement of cervical spinal cord cross-sectional area by MRI using edge detection and partial volume correction. J Magn Reson Imaging 21(3):197–203CrossRefPubMed

30.

Agosta F, Filippi M (2007) MRI of spinal cord in multiple sclerosis. J Neuroimaging 17(Suppl 1):46S–49SCrossRefPubMed

31.

Agosta F, Lagana M, Valsasina P et al (2007) Evidence for cervical cord tissue disorganisation with aging by diffusion tensor MRI. Neuroimage 36(3):728–735CrossRefPubMed

32.

Valsasina P, Horsfield MA, Rocca MA, Absinta M, Comi G, Filippi M (2012) Spatial normalization and regional assessment of cord atrophy: voxel-based analysis of cervical cord 3D T1-weighted images. AJNR Am J Neuroradiol 33(11):2195–2200CrossRefPubMed

33.

Yanase M, Matsuyama Y, Hirose K et al (2006) Measurement of the cervical spinal cord volume on MRI. J Spinal Disord Tech 19(2):125–129CrossRefPubMed

34.

Cruz-Sanchez FF, Moral A, Tolosa E, de Belleroche J, Rossi ML (1998) Evaluation of neuronal loss, astrocytosis and abnormalities of cytoskeletal components of large motor neurons in the human anterior horn in aging. J Neural Transm 105(6–7):689–701CrossRefPubMed

Titel: A longitudinal MRI study of cervical cord atrophy in multiple sclerosis
verfasst von: Paola Valsasina
Maria A. Rocca
Mark A. Horsfield
Massimiliano Copetti
Massimo Filippi
Publikationsdatum: 01.07.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Neurology / Ausgabe 7/2015
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-015-7754-z

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2015

Walking function in clinical monitoring of multiple sclerosis by telemedicine

Impulsive aggressive obsessions following cerebellar strokes: a case study

Whole exome sequencing and the clinician: we need clinical skills and functional validation in variant filtering

Brainstem raphe and substantia nigra echogenicity in idiopathic REM sleep behavior disorder with comorbid depression

Functional neural substrates of posterior cortical atrophy patients